SK’s Yozma and BioLeaders to invest $12 mln in Israeli anti cancer tech

South Korea (SK)-based venture capital firm Yozma Group and clinical stage biopharmaceutical company BioLeaders Corp. plan to commit circa $12 million in Israeli anti-cancer technology, based on technology developed at the Weizmann Institute of Science.

In addition, Yozma Group Asia, a unit of Israel's The Yozma Group, will inject $2 million in On-Sight Medical Inc., jointly owned by Yeda Research & Development Co. Ltd., New York University Medical School and other parties.

Currently, On-Sight Medical is developing an easy-to-use ultrasound technology that patients may use on their own and analyze the results.

Once in service, the technology will solve the deficit in the numbers of trained technicians, as well as help, ease the workload in hospitals.